NASDAQ
Kymera Therapeutics, Inc. (KYMR) has a free cash flow growth of -33.54% as of Friday, May 29, 2026. This represents a 44.18% decrease compared to its 12-month average of -23.26%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.